Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release

Peter A. Crooks, Joshua T. Ayers, Rui Xu, Sangeetha P. Sumithran, Vladimir P. Grinevich, Lincoln H. Wilkins, A. Gabriela Deaciuc, David D. Allen, Linda P. Dwoskin

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

N-n-Alkylation of nicotine converts it from an agonist into an antagonist at neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogues exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.

Original languageEnglish
Pages (from-to)1869-1874
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume14
Issue number8
DOIs
StatePublished - Apr 19 2004

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release'. Together they form a unique fingerprint.

Cite this